BioSpace News Archive

Spero Therapeutics, Inc. today announced that it will host a conference call and live audio webcast on Wednesday, March 13, 2024 at 4:30 p.m. ET to report its fourth quarter and full year financial results.

Apnimed, Inc. today announced the company will participate in the Leerink Partners Global Biopharma Conference taking place in Miami on March 11-13, 2024.

Aerovate Therapeutics, Inc. today announced that its Board of Directors has elected current Board member, Habib Dable, as Chair of the Board.

Innate Pharma SA announced that an abstract regarding its preclinical asset IPH45, a novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate targeting Nectin-4, has been selected for oral presentation at the American Association for Cancer Research Annual Meeting 2024, taking place April 5-10 in San Diego, California.

Tandem Diabetes Care, Inc. announced the pricing of $275.0 million aggregate principal amount of 1.50% Convertible Senior Notes due 2029 in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

GenSight Biologics announced that recent prospective real-world data from early access programs confirm the benefit of LUMEVOQ® in patients with Leber Hereditary Optic Neuropathy from the ND4 mutation, as observed in clinical trials.

Medivir AB announces that the company will participate at the Swiss Nordic Bio conference on March 7, 2024.

Ryvu Therapeutics announced that preclinical data from its synthetic lethality pipeline and RVU120 project, as well as on MEN1703, will be presented at the upcoming 2024 AACR Annual Meeting, scheduled for April 5-10 in San Diego, California.

Affimed N.V. announced that the Company, with prior approval of the Company’s supervisory board and management board, intends to effect a 1-for-10 reverse stock split of its outstanding common shares, par value €0.01 per share.

Innate Pharma SA announced the first patient was dosed in its Phase 1/2 multicenter trial, investigating the safety and tolerability of IPH6501 in patients with Relapsed and/or Refractory CD20-expressing B-cell Non-Hodgkin’s Lymphoma.